Conolidine’s analgesic effects stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors while in the central anxious procedure, conolidine modulates alternate molecular targets. A Science Improvements study uncovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://georgev320bef1.wikipresses.com/user